Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market

Over the past two years, Novo Nordisk (NYSE: NVO) has lost its lead in the anti-obesity space to its biggest competitor, Eli Lilly (NYSE: LLY). The Denmark-based pharmaceutical leader has tried several things to bounce back, including new drug launches and label expansions for its famous weight management medicine, Wegovy. Novo Nordisk has also worked on making the drug more accessible, and a recent move it announced along those lines could help it expand the market. Here's what investors should know.Image source: Getty Images.First, it's essential to note that, despite the popularity of GLP-1 drugs, many patients who could benefit from them are not currently taking them. Here's how we know that. As of a few years ago, about 40.3% of adults in the U.S. were obese, using the standard definition of having a body mass index (BMI) equal to or above 30. This definition has some drawbacks. Insofar as excess weight is dangerous, the risk comes mostly from visceral fat, which is stored in the abdomen region. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool